Rating Buzzer: Achaogen (NASDAQ:AKAO) Gets Better Rating From Cowen & Co.. What Is The Stock Target?

November 28, 2016 - By Marguerite Chambers

Rating Buzzer:  Achaogen (NASDAQ:AKAO) Gets Better Rating From Cowen & Co.. What Is The Stock Target?

Achaogen (NASDAQ:AKAO) Upgrade

Cowen & Co. gave Achaogen (NASDAQ:AKAO) shares a new “Outperform” rating in a analysts note issued to investors and clients on Monday morning. This is upgrade from the last “Market Perform” rating.

Achaogen Inc (NASDAQ:AKAO) Ratings Coverage

Out of 4 analysts covering Achaogen (NASDAQ:AKAO), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Achaogen has been the topic of 4 analyst reports since March 16, 2016 according to StockzIntelligence Inc. Needham downgraded the shares of AKAO in a report on Wednesday, March 16 to “Hold” rating. The stock has “Market Perform” rating given by Cowen & Co on Thursday, March 31. The firm has “Outperform” rating given on Tuesday, June 14 by Wedbush. Aegis Capital initiated the stock with “Buy” rating in Wednesday, November 2 report.

About 319,846 shares traded hands or 14.60% up from the average. Achaogen Inc (NASDAQ:AKAO) has risen 35.28% since April 25, 2016 and is uptrending. It has outperformed by 29.26% the S&P500.

Analysts await Achaogen Inc (NASDAQ:AKAO) to report earnings on March, 21. They expect $-0.47 EPS, up 22.95% or $0.14 from last year’s $-0.61 per share. After $-0.41 actual EPS reported by Achaogen Inc for the previous quarter, Wall Street now forecasts 14.63% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.15, from 1.22 in 2016Q1. The ratio is negative, as 8 funds sold all Achaogen Inc shares owned while 10 reduced positions. 10 funds bought stakes while 12 increased positions. They now own 13.87 million shares or 102.18% more from 6.86 million shares in 2016Q1.

Point72 Asset Management L P, a Connecticut-based fund reported 890,000 shares. Ecor1 Capital Ltd Liability Com holds 2.35% or 1.57M shares in its portfolio. Iconiq Ltd Com, a California-based fund reported 28,629 shares. Baker Bros Advsr Lp has 0% invested in the company for 100,000 shares. Cqs Cayman Ltd Partnership holds 0.03% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 90,850 shares. Eagle Advsr Limited Com holds 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 38,749 shares. Sphera Funds Limited reported 1.26 million shares or 1.24% of all its holdings. Spark Investment Mgmt Ltd has invested 0.01% of its portfolio in Achaogen Inc (NASDAQ:AKAO). Bankshares Of America De accumulated 0% or 32,700 shares. Putnam Investments Ltd Liability Company last reported 123,527 shares in the company. Tower Cap Ltd Com (Trc) holds 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 881 shares. Jacobs Levy Equity Inc holds 0% or 62,572 shares in its portfolio. Acadian Asset Mgmt Limited Liability Corp accumulated 0% or 328 shares. Moreover, Northern Trust Corp has 0% invested in Achaogen Inc (NASDAQ:AKAO) for 15,300 shares. Deutsche Bancshares Ag last reported 0% of its portfolio in the stock.

Insider Transactions: Since September 27, 2016, the stock had 0 buys, and 2 sales for $20,217 net activity. $4,597 worth of Achaogen Inc (NASDAQ:AKAO) was sold by Sarpangal Zeryn. $15,620 worth of shares were sold by Wise Blake on Tuesday, September 27.

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $142.42 million. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant gram-negative infections. It currently has negative earnings. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

According to Zacks Investment Research, “Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.”

AKAO Company Profile

Achaogen, Inc., incorporated on November 26, 2002, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections, which include a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. The Company’s development plan for plazomicin includes over two Phase III clinical trials.

Another recent and important Achaogen Inc (NASDAQ:AKAO) news was published by Globenewswire.com which published an article titled: “Achaogen to Present First Plazomicin CARE Trial Data in Patients with …” on October 24, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>